Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study. by Davidson, J.E. et al.
RESEARCH Open Access
Plasma lipoprotein-associated phospholipase A2
activity in Alzheimer’s disease, amnestic mild
cognitive impairment, and cognitively healthy
elderly subjects: a cross-sectional study
Julie E Davidson1,2*, Andrew Lockhart3, Leslie Amos4, Heide A Stirnadel-Farrant1, Vincent Mooser5,
Marc Sollberger2, Axel Regeniter6, Andreas U Monsch2 and Michael C Irizarry7
Abstract
Introduction: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a circulating enzyme with pro-inflammatory
and oxidative activities associated with cardiovascular disease and ischemic stroke. While high plasma Lp-PLA2
activity was reported as a risk factor for dementia in the Rotterdam study, no association between Lp-PLA2 mass
and dementia or Alzheimer’s disease (AD) was detected in the Framingham study. The objectives of the current
study were to explore the relationship of plasma Lp-PLA2 activity with cognitive diagnoses (AD, amnestic mild
cognitive impairment (aMCI), and cognitively healthy subjects), cardiovascular markers, cerebrospinal fluid (CSF)
markers of AD, and apolipoprotein E (APOE) genotype.
Methods: Subjects with mild AD (n = 78) and aMCI (n = 59) were recruited from the Memory Clinic, University
Hospital, Basel, Switzerland; cognitively healthy subjects (n = 66) were recruited from the community. Subjects
underwent standardised medical, neurological, neuropsychological, imaging, genetic, blood and CSF evaluation.
Differences in Lp-PLA2 activity between the cognitive diagnosis groups were tested with ANOVA and in multiple
linear regression models with adjustment for covariates. Associations between Lp-PLA2 and markers of
cardiovascular disease and AD were explored with Spearman’s correlation coefficients.
Results: There was no significant difference in plasma Lp-PLA2 activity between AD (197.1 (standard deviation, SD
38.4) nmol/min/ml) and controls (195.4 (SD 41.9)). Gender, statin use and low-density lipoprotein cholesterol (LDL)
were independently associated with Lp-PLA2 activity in multiple regression models. Lp-PLA2 activity was correlated
with LDL and inversely correlated with high-density lipoprotein (HDL). AD subjects with APOE-ε4 had higher Lp-
PLA2 activity (207.9 (SD 41.2)) than AD subjects lacking APOE-ε4 (181.6 (SD 26.0), P = 0.003) although this was
attenuated by adjustment for LDL (P = 0.09). No strong correlations were detected for Lp-PLA2 activity and CSF
markers of AD.
Conclusion: Plasma Lp-PLA2 was not associated with a diagnosis of AD or aMCI in this cross-sectional study. The
main clinical correlates of Lp-PLA2 activity in AD, aMCI and cognitively healthy subjects were variables associated
with lipid metabolism.
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Introduction
Lipoprotein-associated phospholipase A2 (Lp-PLA2), also
known as platelet activating factor acetylhydrolase (PAF-
AH), is a circulating enzyme with pro-inflammatory and
oxidative activities studied extensively as a marker of car-
diovascular risk [1-3]. LpPLA2 is measured through assay
of either enzyme concentration in the serum (mass) or
enzymatic activity [3]. While other cardiovascular risk
factors, such as hypertension, hyperlipidemia and dia-
betes, may increase the risk of developing dementia and
Alzheimer’s disease (AD) [4], there is limited published
epidemiological data regarding the relationship between
Lp-PLA2 activity and dementia. Individuals aged ≥ 55
years old within the highest quartile of Lp-PLA2 activity
had an increased risk of developing dementia over a
mean follow-up of 5.7 years in the Rotterdam case-cohort
study (HR 1.56; CI 1.03 to 2.37); the effect was greater on
vascular dementia (HR 2.19, CI 0.80 to 6.03) than for the
AD outcome (HR 1.30, CI 0.82 to 2.04) [5]. Lp-PLA2
mass (measured as a one standard deviation increase
above mean) was not found to be associated with an
increased risk of dementia (HR 0.98; CI 0.84 to 1.15) or
AD (HR 0.98; CI 0.82 to 1.18) in the Framingham Study,
however [6]. Apolipoprotein E (APOE) polymorphisms
related to AD risk influence Lp-PLA2 activity levels [7],
yet the null activity polymorphism of the Lp-PLA2 gene
was not associated with lower risk of AD in a large case-
control study in Japan [8].
The principal aim of this study was to examine whether
plasma Lp-PLA2 activity differed by diagnosis (AD, aMCI,
cognitively healthy) in a clinically well characterised group
of subjects. Such a finding could be used to support the
rationale for the development of Lp-PLA2 modifying treat-
ments for use in populations with, or at risk for, dementia.
Additional objectives included: (i) exploring the associa-
tions between Lp-PLA2 and cerebrospinal fluid (CSF) mar-
kers of AD, (ii) assessing the association of Lp-PLA2 and
markers of cardiovascular disease or diabetes in individuals
with dementia, and (iii) investigating the relationship
between Lp-PLA2 and APOE genotype.
Materials and methods
Subjects
Subjects with AD (by National Institute of Neurological
and Communicative Disorders and Stroke - Alzheimer’s
Disease and Related Disorders Association (NINCDS-
ADRDA) [9] criteria, n = 78), amnestic MCI (aMCI) (by
Petersen criteria, [10]n = 59), and cognitively healthy
“normal controls” (n = 66) were recruited at the Memory
Clinic, Department of Geriatrics, University Hospital,
Basel, Switzerland, and underwent detailed neuropsycho-
logical, clinical, biomarker and imaging assessments at
baseline and 12 months post-baseline. All study partici-
pants were aged ≥ 50 and had between 7 and 20 years of
education. Subjects with AD and aMCI were current
clinic patients. Controls were identified from the partici-
pants of the Basel Study on the Elderly (BASEL Project)
described elsewhere; recruitment was stratified to ensure
an even distribution of controls across each decade of
age (50 to 59, 60 to 69, 70 to 79 and 80 to 89) and across
genders [11]. The study protocol was approved by the
University of Basel Institutional Review board and writ-
ten informed consent was obtained from each patient.
The current study is a cross-sectional analysis of data col-
lected at the baseline study visit.
Laboratory procedures
Plasma aliquots, extracted from baseline blood samples
and stored at -80°C, were transferred to Quest Diagnos-
tics Inc. for Lp-PLA2 enzymatic activity measurement
using an established colorimetric activity method
(CAM) [12]. The upper limit of valid measurement for
the CAM assay is 300 nmol/min/ml and subjects (n =
6) with values greater than or equal to 300 nmol/min/
ml were assigned a value of 300 nmol/min/ml. Markers
of AD in CSF – total Tau (T-Tau), phosphorylated Tau,
181P-epitope (P-Tau), and amyloid beta protein 42
(Aß42) – were collected at the baseline visit and mea-
sured by ELISA at the University of Basel using the
manufacturer’s recommended protocols (Innogenetics
NV, Ghent, Belgium).
Statistical analysis
Differences in mean Lp-PLA2 activity between diagnosis
groups (AD, aMCI and normal controls) were explored
initially using ANOVA. The primary comparison of
interest was between AD and normal controls. The
study was powered to detect a difference of 20 nmol/
min/ml with 90% power and a two-sided alpha of 0.05,
assuming a mean (SD) of 144 (36) nmol/min/ml in the
normal controls [13].
Potential confounders or modifiers of the relationship
between AD and aMCI and Lp-PLA2 were explored in a
multiple linear regression model using backwards elimina-
tion with a retention criterion of P < 0.1. Covariates
included in the models were statin use (yes/no), age, gen-
der, body mass index (BMI), European Cardiovascular
Society (ESC) cardiovascular risk score [14] of > 5%, his-
tory of diabetes type 1 or 2, history of heart disease,
Hachinksi ischaemia score [15], and white matter changes
(Scheltens [16] and Wahlund scores [17]). Statin use, age
and gender were forced to remain in the model given
demonstrated associations between these factors and
dementia or Lp-PLA2 activity [18-20].
Lp-PLA2 is largely bound to LDL in the circulation,
possibly through apolipoprotein B (apoB) 100 [21], and
whether or not to adjust analytically for apoB and/or
LDL in studies of Lp-PLA2 and cardiovascular outcomes
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is a matter for current scientific debate [3,22]. While it is
important to assess whether any observed associations of
Lp-PLA2 with dementia may simply be proxies for an
effect of LDL, controlling for LDL analytically could
result in over-correction of the LpPLA2 values, obscuring
a true association. To address this, the effect of LDL was
explored by adjusting the final linear regression model
arrived at through backwards elimination for LDL to
assess whether this improved the model (assessed by
comparison of model R2, BIC and AIC). Reporting mod-
els both with and without adjustment for LDL is an
approach used in the cardiovascular field [3]. Ten sub-
jects with data missing for at least one covariate were
dropped from the backwards elimination modelling.
The secondary analyses of the correlates of Lp-PLA2
activity were exploratory, and were not adjusted for multi-
ple comparisons. Spearman’s correlation coefficients were
used to explore the association between Lp-PLA2 activity
and (i) CSF markers of AD (Aß42, T-Tau and P-Tau),
(ii) white matter changes (Scheltens score) and (iii) mar-
kers of cardiovascular disease and diabetes (LDL, high-
density lipoprotein (HDL), total cholesterol:HDL ratio,
homocysteine and haemoglobin A1c (HgbA1C)). Student’s
t-tests were used to test for differences in mean Lp-PLA2
by APOE ε4 genotype (positive (1 or 2 ε4 alleles) versus
negative (0 ε4 alleles)). Multiple linear regression was used
to adjust the APOE ε4 comparison in the AD group for
covariates (statin use, heart disease and LDL; explored in
separate models).
All analyses were performed using SAS software, Ver-
sion 9.1 for Windows. Copyright, SAS Institute Inc. SAS
and all other SAS Institute Inc. product or service names
are registered trademarks or trademarks of SAS Institute
Inc., Cary, NC, USA.
Results
Subject demographics
The demographic characteristics of the subjects are
shown in Table 1. The groups differed in terms of age
(P = 0.0005), gender (P = 0.02), education (P = 0.0005),
homocysteine (P = 0.002), HDL (P = 0.005), Scheltens
score [16] (P = 0.002), Wahlund score [17] (P = 0.04),
Hachinski ischemia score [15] (P < 0.0001), CSF T-tau
(P < 0.0001) and CSF P-tau (P < 0.0001); values were
higher in the AD group than in the normal control
group while values in the aMCI group were intermedi-
ate. Similarly, differences were detected across the
groups for total cholesterol:HDL ratio (P = 0.01) and
CSF Ab42 (P < 0.0001); values for these measures were
lower in the AD group than in the normal control
group and, again, values in the aMCI group were inter-
mediate. The mean score on the Mini Mental Status
Examination (MMSE) [23] in AD subjects was consis-
tent with mild dementia
Plasma Lp-PLA2 activities
Mean plasma Lp-PLA2 activities were generally higher
across all groups (195 to 206 nmol/min/ml) compared to
those reported previously in the literature (144 to 146
nmol/min/ml) using the CAM assay [13,19] (Table 1 and
Figure 1). There was no significant difference in Lp-PLA2
activity levels between the control group and the AD
group (mean difference 1.7 nmol/min/ml, SD 6.8, P =
0.81) or aMCI group (mean difference 10.1 nmol/min/
ml, SD 7.4, P = 0.17) in the unadjusted comparison.
Results from the backwards elimination multiple lin-
ear regression model without LDL and for this model
with adjustment for LDL are presented in Table 2. The
model with adjustment for LDL had greater explana-
tory power than the model without LDL (F = 22.39,
P < 0.0001, R2 = 0.42 versus F = 3.6, P = 0.0012, R2 =
0.12, respectively; BIC and AIC both confirmed an
improvement in fit). In both models female gender was
associated with lower Lp-PLA2 activity. Statin use was
also associated with lower Lp-PLA2 activity levels com-
pared to non-use although this effect was attenuated
after adjustment for LDL. In the model without LDL,
increased BMI was a significant predictor of Lp-PLA2
activity; as with statin use, the effect of BMI was atte-
nuated after adjustment for LDL. LDL was the stron-
gest independent predictor of Lp-PLA2 activity in the
model with LDL; a 1 mmol/L increase in LDL was
associated with a 24.1 nmol/min/ml increase in Lp-
PLA2 activity. Lp-PLA2 activity levels in aMCI trended
higher relative to control subjects but the difference
only reached statistical significance in the model which
included LDL.
Plasma Lp-PLA2 activity did not correlate with CSF
biomarkers nor with white matter changes within diag-
noses, apart from a marginally significant inverse asso-
ciation with CSF Ab42 in aMCI (r = -0.29, P = 0.03)
(Table 3).
Correlations between plasma Lp-PLA2 and plasma mar-
kers of cardiovascular disease or diabetes were similar in
magnitude and direction across diagnosis groups. Lp-
PLA2 was correlated with LDL and total cholesterol:HDL
ratio (r = 0.51 and 0.54, respectively, P < 0.001 in the total
pooled sample) and inversely correlated with HDL (r =
-0.32, P < 0.001). Lp-PLA2 was not associated with homo-
cysteine or HgbA1c.
Lp-PLA2 levels tended to be higher in individuals who
were APOE ε4 carriers in each diagnosis group (Table 4)
In the AD diagnosis group, mean Lp-PLA2 activity was
26.2 nmol/min/l higher in individuals with APOE ε4 posi-
tive status compared to APOE ε4 negative individuals (P =
0.003). Adjustment for LDL levels removed this effect,
however (P = 0.09). LDL levels also tended to be increased
in APOE ε4 carriers and this difference was greatest in the
AD group (P = 0.05).
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Discussion
Findings from the Rotterdam Study suggested that Lp-
PLA2, implicated in cardiovascular disease, could also be a
risk factor for dementia [5] whereas analyses from the
Framingham Study failed to replicate this association [6].
To our knowledge there have been no previously pub-
lished studies of plasma Lp-PLA2 activity in established
aMCI, a potential pre-stage of AD. In the current study,
we detected no differences in Lp-PLA2 activity levels in
cross-sectional comparisons among AD, aMCI and cogni-
tively healthy subjects. Lp-PLA2 activity levels were mod-
erately elevated in aMCI relative to control subjects after
adjustment for LDL, but this requires further exploration
in follow-up studies.
Lp-PLA2 activity was found to be associated with car-
riage of the APOE ε4 allele; however, this effect was
removed after adjustment for LDL. An association
between Lp-PLA2 activity and APOE genotype has been
reported previously in a single gene study [24]. A recent
genome-wide association study found that the G allele of
the rs4420638 single-nucleotide polymorphism (SNP) in
APOE was associated with increased Lp-PLA2 activity; the
authors suggest that Lp-PLA2 activity would be expected
Table 1 Characteristics of subjects
Characteristic AD
(n = 78)
aMCI
(n = 59)
Normal Control
(n = 66)
P*
Demographic
Age, y (mean, SD) 75.7 (8.4) 71.3 (8.5) 71.1 (8.3) 0.0005
Female, N (%) 47 (60%) 28 (43%) 24 (36%) 0.017
Education, y (mean, SD) 11.4 (2.8) 12.8 (3.5) 13.1 (2.7) 0.0005
Clinical
Statin Use, N (%) 16 (21%) 17 (28.8%) 11 (17%) 0.26
BMI (mean, SD) 25.4 (3.2) 25.6 (3.9) 24.6 (3.7) 0.33
ESC score (mean, SD) 0.133 (0.110) 0.094 (0.102) 0.103 (0.078) 0.015
Diabetes type 1 or 2, N (%) 6 (7.7%) 1 (1.7%) 3 (4.5%) 0.30
History of heart disease, N (%) 8 (10.3%) 9 (15.3%) 7 (10.6%) 0.68
Hachinski score (mean, SD) 2.6 (1.9) 2.5 (2.6) 0.7 (1.0) < 0.0001
Scheltens score (mean, SD) 12.2 (9.9) 10.8 (10.8) 6.4 (5.7) 0.0021
Wahlund score (mean, SD) 4.0 (2.7) 3.7 (2.8) 2.8 (1.7) 0.04
Duration of symptoms, y (mean, sd) 2.5 (2.4) 3.1 (3.3) NA 0.63
MMSE, mean (mean, SD) 23.8 (2.7) 28 (1.7) 29.1 (1.0) < 0.0001
Laboratory
LpPLA2, nmol/min/ml (mean, SD) 197.1 (38.4) 205.5 (43.4) 195.4 (41.9) 0.34
LDL, mmol/L (mean, SD) 2.9 (1.0) 2.9 (0.8) 3.0 (1.2) 0.79
HDL, mmol/L (mean, SD) 2.0 (0.5) 1.8 (0.5) 1.7 (0.5) 0.005
Total cholesterol:HDL ratio 3.0 (0.9) 3.2 (0.9) 3.5 (1.2) 0.012
Homocysteine, Umol/L (mean, sd) 15.1 (5.4) 14.1 (7.9) 12.3 (3.4) 0.002
HbA1c, % (SD) 5.6 (0.4) 5.6 (0.4) 5.5 (0.3) 0.43
CSF markers of AD
Ab42, pg/ml (mean, SD) 421.4 (147.6) 568.2 (251.7) 809.7 (260.5) < 0.0001
CSF T-Tau, pg/ml (mean, SD) 698.5 (317.2) 417.2 (245.6) 308.0 (195.9) < 0.0001
CSF P-Tau, pg/ml (mean, SD) 101.9 (58.0) 62.9 (27.9) 52.0 (21.6) < 0.0001
Genetic
APOE ε4-positive, N (%) 45 (58%) 30 (50.5%) 4 (6%) NA†
*ANOVA for normally distributed continuous variables, Kruskal-Wallis test for non-normal continuous variables, Fisher’s exact test for ordinal variables. † Control
selection was not independent of APOE status.
Figure 1 Lp-PLA2 activity by diagnosis group.
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to be increased in carriers of APOE ε4, given patterns of
linkage disequilibrium between rs4420638 and the APOE
ε2, ε3 and ε4 genotypes [25]. The correlations observed
between Lp-PLA2 and LDL and between Lp-PLA2 and
HDL across the diagnosis groups in our study reflect the
findings of previous studies in the general population
[19,26,27]. This suggests that mild AD and aMCI are not
associated with an alteration in the relationships between
these markers.
No strong correlations between Lp-PLA2 and CSF bio-
markers for AD were observed in our study; the weak
inverse association between Lp-PLA2 and CSF Ab42 in
the aMCI group (P = 0.041) may represent a false posi-
tive result from the multiple comparisons performed.
The current study identified the expected associations
between AD diagnosis and levels of CSF Ab42 and tau pro-
teins relative to normal controls [28] and between Lp-PLA2
activity and blood lipids, gender and statin use [3]. These
results increase confidence around the accuracy of the
diagnostic classifications and biochemical measurements.
However, the results of the study should be interpreted in
the context of potential limitations of the biochemical mea-
surements. First, the mean Lp-PLA2 activity observed in
the control group (195.4 nmol/min/ml, SD 41.9) was
higher than anticipated, based on levels observed in the
Framingham Offspring study (144 nmol/min/ml, SD 36)
[13] and the Dallas Heart Study (146 nmol/min/ml, SD 40)
[19]. These differences may be related to cohort differ-
ences, such as the older mean age of the current study
population, or assay factors. Secondly, the upper end of the
valid range of assay sensitivity was determined by the assay
manufacturers to be 300 nmol/min/ml. Six subjects (two
with AD and four with aMCI) had Lp-PLA2 activity results
that exceeded this value and were truncated accordingly.
The effect of this truncation on the analyses cannot be
quantified but it is likely that the effect would be to bias
findings towards the null. Finally, this study evaluated Lp-
PLA2 activity in plasma. The physiology of the blood-brain
barrier and the biochemical complexity of plasma may
limit plasma Lp-PLA2 activity/mass as a marker of central
nervous system physiology [29]. A specific Lp-PLA2 activity
has recently been reported to be present in human cere-
brospinal fluid (CSF) [30] and as this biofluid more closely
reflects the composition of the brain extracellular space,
may have a higher yield in biomarker evaluation [31].
Conclusions
The principal correlates of Lp-PLA2 activity in analyses
of our small cross-sectional study were variables involved
in lipid metabolism (LDL, HDL, total cholesterol:HDL
ratio and statin use) and variables influencing lipid meta-
bolism (APOEε4 and gender). Although there were sug-
gested associations between aMCI and elevated Lp-PLA2
levels, and between CSF Ab42 and Lp-PLA2 activity in
the aMCI group, the results must be interpreted with
caution until replicated in further studies given the small
sample size and multiple comparisons associated with
the current study.
Table 2 Final linear regression models of Lp-PLA2 activity by diagnosis group
Model Without LDL Model With LDL
b (SE)† P b (SE)† P
AD (versus Control)* 7.7 (7.2) 0.29 8.3 (5.7) 0.15
aMCI (versus Control)* 11.3 (7.2) 0.12 11.6 (5.8) 0.05
Age (1 year increase)* -0.19 (0.3) 0.58 0.39 (0.3) 0.16
Statin use (yes versus no)* -23.9 (7.0) 0.001 -11.2 (5.8) 0.06
Gender (female versus male)* -10.6 (6.2) 0.09 -23.8 (4.9) < .0001
LDL (1 mmol/l increase) NA NA 24.1 (2.5) < .0001
BMI 1.8 (0.8) 0.03 0.4 (0.69) 0.55
Diabetes Type 2 (yes versus no) -23.3 (14.0) 0.10 -2.7 (11.6) 0.81
Final models selected through backwards elimination. Covariates with P-value < 0.05 are presented in bold. *Forced to remain in the model. † b estimates
correspond to the expected difference in mean Lp-PLA2 activity relative to comparator for binary variables or per one unit increase in continuous covariates.
Table 3 Correlation between plasma Lp-PLA2 and (1) CSF biomarkers for AD and (2) Schelten Score for white matter
changes
-ß- amyloid(1-42) P-Tau (181P epitope) T-Tau Schelten Score
r (P) r (P) r (P) r (P)
AD (n = 78) -0.01 (0.91) -0.20 (0.08) -0.10 (0.40) -0.03 (0.82)
aMCI (n = 59) -0.29 (0.03) -0.08 (0.54) -0.14 (0.28) 0.20 (0.12)
Normal controls
(n = 28 (CSF tests); n = 66 (Scheltens))
-0.17 (0.39) 0.35 (0.07) 0.27 (0.16) -0.06 (0.63)
Correlations with P-value < 0.05 are presented in bold.
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